Novel anticoagulants include dabigatran, rivaroxaban and apixaban. Based on the RE-LY study, a 150-mg dose of dabigatran as compared with warfarin was shown to reduce the rate of stroke ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status. Impaired kidney function is the principal predictor of hemorrhage in ...

USA: A recent subgroup analysis from the OCEANIC-AF randomized clinical trial highlights that asundexian, a novel oral Factor XIa inhibitor, may offer a favorable balance of safety and efficacy ...